Welcome to our dedicated page for Deciphera Pharmaceuticals news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharmaceuticals stock.
Deciphera Pharmaceuticals, Inc. (symbol: DCPH) is a biotechnology company founded in 2003 with a deep scientific understanding of kinase inhibitors. Based in Boston, with research capabilities near the University of Kansas, Deciphera specializes in developing advanced kinase-inhibiting drugs for cancer and immunological diseases. The company has identified small molecule leads for over 50 kinase targets and has built a robust pipeline of drug candidates, including three clinical-stage and two research-stage programs.
The company's lead drug candidate, DCC-2618, is designed to inhibit mutant or amplified KIT and Pdgfra kinases, which drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, Deciphera is developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib, which are focused on treating different types of cancers.
Geographically, Deciphera's operations are concentrated in the United States. The company has recently achieved significant milestones, including the successful completion of a tender offer by Ono Pharmaceutical Co., Ltd. to acquire all outstanding shares of Deciphera for approximately $2.4 billion. Following this acquisition, Deciphera became a wholly owned subsidiary of Ono, who will leverage its research and development capabilities in oncology and its sales power in Europe and the United States to expand its global presence.
The merger with Ono Pharmaceutical marks a new phase for Deciphera, where the combined expertise and resources are expected to accelerate the growth of their pipeline and contribute significantly to the global fight against cancer and other diseases.
Deciphera Pharmaceuticals (DCPH) presented at the ESMO Congress 2021, highlighting significant results from their studies on rebastinib and vimseltinib. Rebastinib, in combination with paclitaxel, achieved a median progression-free survival of 9.1 months in platinum-resistant ovarian cancer patients. A pivotal Phase 3 study for rebastinib is planned for 2022, pending regulatory approval. Vimseltinib showed an objective response rate of 47% in tenosynovial giant cell tumor patients, with a Phase 3 study expected to start in Q4 2021.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will host a virtual investor event on September 17, 2021, from 10:00 AM to 12:30 PM ET, to discuss clinical data for rebastinib and vimseltinib ahead of the ESMO Congress 2021. Key speakers include Dr. Robert L. Coleman and Dr. William D. Tap. The event will be webcast live and available for replay on Deciphera's website. Deciphera is committed to developing innovative cancer treatments, highlighted by its FDA-approved drug QINLOCK, used for fourth-line gastrointestinal stromal tumors.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will participate in a fireside chat at the 19th Annual Morgan Stanley Global Healthcare Conference on September 9, 2021, at 2:45 PM ET. The conference will be held virtually, and a live webcast will be available on the company's website. Deciphera focuses on developing new medicines for cancer treatment, including QINLOCK®, its FDA-approved drug for fourth-line gastrointestinal stromal tumor (GIST), also approved in Australia, Canada, China, and Hong Kong.
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported Q2 2021 financial results, achieving $23.6 million in total revenue, including $22.0 million from QINLOCK sales. R&D expenses rose to $60.0 million due to ongoing studies. Despite these efforts, the company posted a net loss of $70.4 million, slightly higher than the previous year. QINLOCK continues its expansion with approvals in China and upcoming EMA decisions. Key milestones include reporting Phase 3 study data and initiating new trials in late 2021.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its second quarter 2021 financial results on August 3, 2021. The management team will host a conference call at 4:30 PM ET on the same day to discuss the results and provide corporate updates. Investors can access the call by dialing the provided numbers or via the webcast on the Company’s website. Deciphera focuses on developing innovative treatments for cancer, including its FDA-approved QINLOCK® for gastrointestinal stromal tumors.
Deciphera Pharmaceuticals (NASDAQ: DCPH) has initiated dose administration for the first patient in a Phase 1 clinical trial of DCC-3116, an investigational ULK kinase inhibitor targeting advanced tumors with RAS or RAF mutations. This study, designed as a multicenter, open-label trial, will evaluate DCC-3116 as a single agent and in combination with trametinib, a FDA-approved MEK inhibitor. The focus is on various cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. DCC-3116 aims to address significant unmet medical needs in oncology through its unique mechanism of inhibiting autophagy.
Deciphera Pharmaceuticals (NASDAQ: DCPH) presented new data at the 2021 ASCO Annual Meeting regarding QINLOCK for advanced gastrointestinal stromal tumor (GIST) and rebastinib for endometrial cancer. The INVICTUS Phase 3 study showed that patients escalating QINLOCK dose to 150 mg BID achieved a median overall survival of 18.4 months. In the rebastinib study, an objective response rate of 33% was noted in endometrial cancer patients. Deciphera aims to finalize development plans for rebastinib and share further results in late 2021.
Deciphera Pharmaceuticals (NASDAQ: DCPH) has announced that Steve Hoerter, President and CEO, will participate in fireside chats at two investor conferences. The Jefferies Virtual Healthcare Conference is set for June 3, 2021, at 1:30 PM ET, and the JMP Securities Life Sciences Conference will follow on June 16, 2021, at 4:00 PM ET. Live webcasts of these events will be accessible on the Company’s Investors page, with replays available for 90 days.
Deciphera specializes in developing new medicines for cancer, utilizing its proprietary kinase inhibitor platform.
Deciphera Pharmaceuticals (NASDAQ:DCPH) reported its Q1 2021 financial results, highlighting a net product revenue of $20.0 million from QINLOCK, including $19.3 million from U.S. sales. The company will initiate a Phase 1b/2 study combining QINLOCK with binimetinib and expects top-line results from the INTRIGUE Phase 3 study in the fourth quarter. R&D expenses increased to $55.7 million. Despite a net loss of $61.3 million, Deciphera's cash position remains strong at $502.2 million, sufficient to fund operations into the first half of 2023.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its first quarter 2021 financial results on May 4, 2021. A conference call to discuss these results and provide corporate updates will follow at 4:30 PM ET on the same day. Interested parties can join the call via toll-free or international numbers and access the live webcast on the Company’s investor relations page. Deciphera specializes in innovative cancer treatments, including QINLOCK®, its FDA-approved therapy for fourth-line gastrointestinal stromal tumors.
FAQ
What is the current stock price of Deciphera Pharmaceuticals (DCPH)?
What is the market cap of Deciphera Pharmaceuticals (DCPH)?
What does Deciphera Pharmaceuticals, Inc. specialize in?
Where is Deciphera Pharmaceuticals based?
What are the key drug candidates in Deciphera's pipeline?
What is DCC-2618 designed to treat?
Who acquired Deciphera Pharmaceuticals and for how much?
What will be the impact of the acquisition by Ono Pharmaceutical on Deciphera Pharmaceuticals?
What is the significance of Deciphera becoming a wholly owned subsidiary of Ono?
What are the research capabilities of Deciphera Pharmaceuticals?
Are Deciphera's operations limited to the United States?
What recent achievements has Deciphera Pharmaceuticals accomplished?
